MSTX Key Stats
- Purified Poloxamer Granted Unique Nonproprietary Name (Vepoloxamer) By U.S. Adopted Names Council PR Newswire 03/11 08:00 ET
- Vista Partners Publishes March 2014 Macroeconomic & Investment Newsletter Marketwired 03/07 09:00 ET
- MAST THERAPEUTICS, INC. Files SEC form 8-K, Unregistered Sale of Equity Securities Yahoo 02/28 16:16 ET
- Vista Partners Updates Coverage on Mast Therapeutics, Inc. (NYSE MKT: MSTX); Price Target $2.25 Marketwired 02/28 09:00 ET
- Mast Therapeutics Completes Acquisition Of Aires Pharmaceuticals, Inc. noodls 02/27 16:52 ET
- Mast Therapeutics To Present At The Cowen & Co. 34th Annual Healthcare Conference On March 3rd noodls 02/25 14:32 ET
- Mast Therapeutics Announces International Expansion Of Phase 3 "EPIC" Study Of MST-188 noodls 02/24 09:15 ET
- MAST THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Yahoo 02/24 08:02 ET
- Mast Therapeutics Provides Additional Results From Nonclinical Heart Failure Study noodls 02/18 09:14 ET
- The Bull Case For Mast Therapeutics Just Got Even Brighter With Its Recent Acquisition Yahoo 02/12 07:15 ET
MSTX Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Mast Therapeutics is up 10.50% over the last year vs S&P 500 Total Return up 24.21%, Ohr Pharmaceutical up 279.3%, and GlycoMimetics up N/A.
Balance Sheet View Statement
Pro Ratings for MSTX
Pro Strategies Featuring MSTX
Did Mast Therapeutics make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
- Sector: Healthcare
- Industry: Biotechnology
- Headquarters Country: United States
- Headquarters State/Province: California
- Incorporation Country: United States
- Incorporation State/Province: Delaware
Mast Therapeutics Inc is a biopharmaceutical company develops novel therapies for serious or life-threatening diseases with significant unmet needs.